IL1B and ischemic stroke: Silencing HDAC9 has been shown to reduce infarct size, suppress pro-inflammatory cytokine expression (e.g., IL-1β, TNF-α, IL-6), and improve neurological function, underscoring its potential as a therapeutic target in ischemic stroke [65,170].